Azeria Therapeutics

Azeria Therapeutics is the world's first drug discovery company developing breakthrough treatments for patients with hormone-resistant breast and prostate cancer. Azeria is developing a series of small molecules designed to selectively inhibit pioneer factors. Azeria’s initial target is the critical pioneer factor FOXA1, which has been shown to play a key role in the tumorigenesis and maintenance of estrogen receptor (ER)-positive luminal breast cancer and is also believed to play a crucial role in the development of prostate cancer.